Low-Dose Subcutaneous Cytarabine Does Not Require Dilution
Low-dose cytarabine for subcutaneous administration can be given undiluted directly from the commercially available 100 mg/mL formulation, as the FDA-approved product is already in a ready-to-use concentration suitable for subcutaneous injection 1.
FDA-Approved Formulation and Administration
The FDA drug label explicitly states that cytarabine injection is supplied as a sterile solution at 100 mg/mL concentration and may be administered subcutaneously without any mention of required dilution 1. The label notes that "rarely patients have noted pain and inflammation at subcutaneous injection sites. In most instances, however, the drug has been well tolerated" 1.
Clinical Practice Evidence
The standard low-dose cytarabine regimen used in clinical trials consistently describes administration as:
- 20 mg subcutaneously twice daily for 10 consecutive days 2
- Given as subcutaneous injection without dilution specifications 3, 4, 5, 6
Multiple studies spanning decades have successfully administered low-dose cytarabine (10-20 mg/m² subcutaneously) without reporting dilution requirements 3, 4, 5, 6. The research literature describes direct subcutaneous injection as the standard method 7.
Practical Considerations
- The 100 mg/mL concentration is appropriate for the small volumes needed for low-dose regimens (typically 0.2-0.4 mL per injection for a 20 mg dose)
- No chemical stability issues arise with undiluted subcutaneous administration
- Dilution is only specifically mentioned in the FDA label for intravenous infusion preparations, where cytarabine can be added to Water for Injection, 5% Dextrose, or Normal Saline 1
Important Caveat
While dilution is not required, ensure you are using the preservative-free preparation if any intrathecal use is planned 1. For routine subcutaneous low-dose administration, the standard formulation is appropriate as supplied.